Biomarin Non Currrent Assets Other vs Common Stock Total Equity Analysis

BMRN Stock

USD 64.85 0.43 0.67%

Biomarin Pharmaceutical financial indicator trend analysis is way more than just evaluating Biomarin Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomarin Pharmaceutical is a good investment. Please check the relationship between Biomarin Pharmaceutical Non Currrent Assets Other and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Non Currrent Assets Other vs Common Stock Total Equity

Non Currrent Assets Other vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomarin Pharmaceutical Non Currrent Assets Other account and Common Stock Total Equity. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Biomarin Pharmaceutical's Non Currrent Assets Other and Common Stock Total Equity is 0.4. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Biomarin Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Biomarin Pharmaceutical's Non Currrent Assets Other and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Biomarin Pharmaceutical are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Non Currrent Assets Other i.e., Biomarin Pharmaceutical's Non Currrent Assets Other and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Selling General Administrative is very stable compared to the past year. As of the 18th of February 2025, Tax Provision is likely to grow to about 4.4 M, while Sales General And Administrative To Revenue is likely to drop 0.20.

	2022	2023	2024	2025 (projected)
Gross Profit	1.6B	1.8B	2.1B	2.2B
Total Revenue	2.1B	2.4B	2.8B	2.9B

Gross Profit Total Revenue

Biomarin Pharmaceutical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock Total Equity	Short Term Investments	Short Term Debt
Total Assets		0.82	0.83	0.89	1.0	0.98	0.56	-0.2	0.57	0.79	0.99	0.31	0.84	0.96	0.74	0.6	0.97	0.91	0.98	0.97	0.96	0.98	0.41	0.71	0.5	0.26
Short Long Term Debt Total	0.82		0.66	0.71	0.8	0.83	0.29	-0.31	0.53	0.95	0.76	0.22	0.92	0.74	0.74	0.67	0.74	0.87	0.82	0.87	0.76	0.87	0.31	0.72	0.45	0.45
Other Current Liab	0.83	0.66		0.66	0.86	0.71	0.29	0.33	0.04	0.7	0.81	0.2	0.62	0.85	0.47	0.41	0.86	0.75	0.72	0.71	0.88	0.82	-0.06	0.41	0.2	0.11
Total Current Liabilities	0.89	0.71	0.66		0.89	0.88	0.47	-0.18	0.67	0.69	0.86	0.17	0.71	0.93	0.58	0.26	0.93	0.86	0.88	0.88	0.88	0.9	0.3	0.54	0.37	0.45
Total Stockholder Equity	1.0	0.8	0.86	0.89		0.96	0.53	-0.14	0.53	0.78	0.99	0.3	0.81	0.97	0.71	0.57	0.98	0.91	0.97	0.95	0.97	0.97	0.36	0.67	0.46	0.23
Property Plant And Equipment Net	0.98	0.83	0.71	0.88	0.96		0.61	-0.38	0.7	0.76	0.97	0.29	0.85	0.91	0.79	0.64	0.92	0.92	1.0	0.98	0.91	0.95	0.53	0.76	0.57	0.25
Net Debt	0.56	0.29	0.29	0.47	0.53	0.61		-0.45	0.42	0.1	0.6	0.17	0.45	0.45	0.62	0.58	0.48	0.35	0.61	0.61	0.47	0.48	0.63	0.61	0.77	-0.25
Retained Earnings	-0.2	-0.31	0.33	-0.18	-0.14	-0.38	-0.45		-0.77	-0.16	-0.2	-0.05	-0.42	-0.03	-0.53	-0.5	-0.04	-0.2	-0.37	-0.37	-0.03	-0.19	-0.77	-0.58	-0.63	-0.11
Accounts Payable	0.57	0.53	0.04	0.67	0.53	0.7	0.42	-0.77		0.45	0.57	0.26	0.57	0.49	0.61	0.36	0.49	0.59	0.69	0.67	0.46	0.56	0.73	0.63	0.47	0.44
Cash	0.79	0.95	0.7	0.69	0.78	0.76	0.1	-0.16	0.45		0.73	0.26	0.88	0.75	0.66	0.57	0.74	0.84	0.77	0.81	0.75	0.86	0.17	0.63	0.31	0.56
Non Current Assets Total	0.99	0.76	0.81	0.86	0.99	0.97	0.6	-0.2	0.57	0.73		0.39	0.78	0.93	0.74	0.61	0.94	0.88	0.97	0.96	0.95	0.93	0.48	0.7	0.47	0.21
Non Currrent Assets Other	0.31	0.22	0.2	0.17	0.3	0.29	0.17	-0.05	0.26	0.26	0.39		0.16	0.17	0.4	0.44	0.2	0.21	0.28	0.33	0.26	0.19	0.52	0.4	-0.04	0.39
Cash And Short Term Investments	0.84	0.92	0.62	0.71	0.81	0.85	0.45	-0.42	0.57	0.88	0.78	0.16		0.74	0.77	0.74	0.74	0.77	0.86	0.9	0.76	0.89	0.41	0.75	0.71	0.34
Net Receivables	0.96	0.74	0.85	0.93	0.97	0.91	0.45	-0.03	0.49	0.75	0.93	0.17	0.74		0.62	0.38	0.99	0.92	0.92	0.89	0.95	0.96	0.2	0.57	0.35	0.29
Common Stock Shares Outstanding	0.74	0.74	0.47	0.58	0.71	0.79	0.62	-0.53	0.61	0.66	0.74	0.4	0.77	0.62		0.83	0.62	0.69	0.79	0.8	0.63	0.72	0.64	1.0	0.61	0.23
Non Current Liabilities Total	0.6	0.67	0.41	0.26	0.57	0.64	0.58	-0.5	0.36	0.57	0.61	0.44	0.74	0.38	0.83		0.41	0.48	0.64	0.68	0.47	0.56	0.65	0.83	0.69	0.0
Inventory	0.97	0.74	0.86	0.93	0.98	0.92	0.48	-0.04	0.49	0.74	0.94	0.2	0.74	0.99	0.62	0.41		0.91	0.93	0.9	0.98	0.96	0.21	0.57	0.38	0.25
Other Current Assets	0.91	0.87	0.75	0.86	0.91	0.92	0.35	-0.2	0.59	0.84	0.88	0.21	0.77	0.92	0.69	0.48	0.91		0.9	0.89	0.87	0.93	0.26	0.65	0.29	0.38
Other Stockholder Equity	0.98	0.82	0.72	0.88	0.97	1.0	0.61	-0.37	0.69	0.77	0.97	0.28	0.86	0.92	0.79	0.64	0.93	0.9		0.98	0.92	0.96	0.52	0.77	0.58	0.25
Total Liab	0.97	0.87	0.71	0.88	0.95	0.98	0.61	-0.37	0.67	0.81	0.96	0.33	0.9	0.89	0.8	0.68	0.9	0.89	0.98		0.9	0.96	0.52	0.78	0.6	0.34
Property Plant And Equipment Gross	0.96	0.76	0.88	0.88	0.97	0.91	0.47	-0.03	0.46	0.75	0.95	0.26	0.76	0.95	0.63	0.47	0.98	0.87	0.92	0.9		0.95	0.24	0.59	0.4	0.22
Total Current Assets	0.98	0.87	0.82	0.9	0.97	0.95	0.48	-0.19	0.56	0.86	0.93	0.19	0.89	0.96	0.72	0.56	0.96	0.93	0.96	0.96	0.95		0.3	0.68	0.52	0.32
Intangible Assets	0.41	0.31	-0.06	0.3	0.36	0.53	0.63	-0.77	0.73	0.17	0.48	0.52	0.41	0.2	0.64	0.65	0.21	0.26	0.52	0.52	0.24	0.3		0.67	0.58	0.12
Common Stock Total Equity	0.71	0.72	0.41	0.54	0.67	0.76	0.61	-0.58	0.63	0.63	0.7	0.4	0.75	0.57	1.0	0.83	0.57	0.65	0.77	0.78	0.59	0.68	0.67		0.62	0.23
Short Term Investments	0.5	0.45	0.2	0.37	0.46	0.57	0.77	-0.63	0.47	0.31	0.47	-0.04	0.71	0.35	0.61	0.69	0.38	0.29	0.58	0.6	0.4	0.52	0.58	0.62		-0.15
Short Term Debt	0.26	0.45	0.11	0.45	0.23	0.25	-0.25	-0.11	0.44	0.56	0.21	0.39	0.34	0.29	0.23	0.0	0.25	0.38	0.25	0.34	0.22	0.32	0.12	0.23	-0.15

Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.8B	6.0B	6.4B	6.8B	7.9B	8.3B
Short Long Term Debt Total	1.1B	1.1B	1.1B	1.1B	1.3B	1.3B
Other Current Liab	289.2M	329.4M	330.3M	351.6M	404.3M	424.5M
Total Current Liabilities	492.5M	539.8M	588.9M	1.2B	1.4B	1.4B
Total Stockholder Equity	4.1B	4.3B	4.6B	5.0B	5.7B	6.0B
Property Plant And Equipment Net	1.0B	1.0B	1.1B	1.1B	1.3B	1.3B
Net Debt	426.0M	491.8M	358.5M	340.6M	391.7M	214.5M
Retained Earnings	(861.6M)	(925.7M)	(789.2M)	(621.6M)	(559.4M)	(587.4M)
Accounts Payable	191.4M	193.0M	231.2M	315.5M	362.8M	381.0M
Cash	649.2M	587.3M	724.5M	755.1M	868.4M	911.8M
Non Current Assets Total	3.5B	3.7B	3.6B	3.9B	4.5B	4.7B
Non Currrent Assets Other	142.2M	151.8M	176.2M	125.5M	144.3M	72.8M
Cash And Short Term Investments	1.1B	1.0B	1.3B	1.1B	1.2B	1.3B
Net Receivables	448.4M	373.4M	461.3M	633.7M	728.8M	765.2M
Common Stock Shares Outstanding	191.7M	182.9M	189.0M	191.6M	220.3M	127.6M
Liabilities And Stockholders Equity	5.8B	6.0B	6.4B	6.8B	7.9B	8.3B
Non Current Liabilities Total	1.2B	1.2B	1.2B	713.0M	820.0M	586.6M
Inventory	698.5M	776.7M	894.1M	1.1B	1.3B	1.3B
Other Current Assets	129.9M	110.4M	104.5M	141.4M	162.6M	170.7M
Other Stockholder Equity	5.0B	5.2B	5.4B	5.6B	6.5B	6.8B
Total Liab	1.7B	1.7B	1.8B	1.9B	2.2B	2.3B
Property Plant And Equipment Gross	1.0B	1.8B	1.9B	1.9B	2.2B	2.3B
Total Current Assets	2.3B	2.3B	2.8B	3.0B	3.4B	3.6B
Accumulated Other Comprehensive Income	(16.1M)	14.4M	(3.9M)	(38.6M)	(34.8M)	(33.0M)
Intangible Assets	417.3M	388.7M	338.6M	294.7M	338.9M	244.4M
Common Stock Total Equity	178K	180K	182K	184K	211.6K	126.8K
Short Term Investments	416.2M	426.6M	567.0M	318.7M	366.5M	276.3M
Short Term Debt	11.8M	10.5M	10.4M	502.7M	578.1M	607.0M
Common Stock	182K	184K	186K	189K	217.4K	133.2K
Other Assets	612.0M	1.6B	1.6B	1.6B	1.8B	1.9B
Long Term Debt	1.1B	1.1B	1.1B	593.1M	682.1M	553.3M
Property Plant Equipment	1.0B	1.0B	1.0B	1.1B	1.3B	1.3B
Current Deferred Revenue	152K	7.0M	711K	4.6M	4.2M	4.4M
Other Liab	98.1M	174.3M	113.7M	73.5M	84.5M	81.8M
Net Tangible Assets	2.5B	3.5B	3.7B	4.1B	4.7B	4.9B
Retained Earnings Total Equity	(1.7B)	(1.7B)	(861.6M)	(925.7M)	(833.1M)	(874.8M)
Long Term Debt Total	830.4M	486.2M	1.1B	1.1B	1.2B	730.7M
Capital Surpluse	4.7B	4.8B	5.0B	5.2B	6.0B	3.7B
Long Term Investments	285.5M	507.8M	333.8M	611.1M	702.8M	353.3M

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.607

Earnings Share

1.66

Revenue Per Share

14.529

Quarterly Revenue Growth

0.283

Return On Assets

0.03

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Non Currrent Assets Other vs Common Stock Total Equity Analysis

Non Currrent Assets Other vs Common Stock Total Equity

Non Currrent Assets Other vs Common Stock Total Equity Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Common Stock Total Equity

Biomarin Pharmaceutical fundamental ratios Correlations

Biomarin Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biomarin Pharmaceutical fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Property Plant And Equipment Net
Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding
Non Current Assets Total	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Inventory	+ 0.99	Net Receivables

Intangible Assets	- 0.77	Retained Earnings
Accounts Payable	- 0.77	Retained Earnings
Short Term Investments	- 0.63	Retained Earnings
Common Stock Total Equity	- 0.58	Retained Earnings
Common Stock Shares Outstanding	- 0.53	Retained Earnings
Non Current Liabilities Total	- 0.5	Retained Earnings